Estrogen receptor degradation: a CUE for endocrine resistance?
Despite the undoubted success of adjuvant endocrine therapies that target the estrogen receptor pathway, not all women with estrogen receptor-positive breast cancer respond to these therapies, and many who initially respond will subsequently relapse. Deregulation of various aspects of estrogen receptor signaling has been highlighted as a mechanism of resistance and as a basis for alternative therapeutic approaches. However, a recent publication refocuses attention on the estrogen receptor itself by showing that the ubiquitin-binding CUE domain-containing protein 2 is a regulator of estrogen receptor protein degradation and a marker of endocrine resistance in breast cancer.
|Responsible Garvan Author|
|Publisher Name||BREAST CANCER RES|
|DOI||bcr2914 [pii] 10.1186/bcr2914|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21861853|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/11101|